Spot Scanning Proton Beam Therapy for Surgery-inaccessible Hepatocellular Carcinoma: Preliminary Results
Yutaka Fujimoto1, Sachika Shiraishi2,3, Masashi Yamanaka4
1Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan.
Background/Aim:
Spot scanning proton beam therapy (SS-PBT) was employed for the treatment of surgery-inaccessible hepatocellular carcinoma, primarily influenced by respiratory movement.
Patients And Methods:
Between October 2022 and December 2023, 12 patients were enrolled in this study to evaluate the efficacy of SS-PBT. The median follow-up time was 13.1 months.
Results:
The one-year survival, progression-free survival, and local control rates were 79.5%, 57.1%, and 100%, respectively, without grade 2 or higher PBT-related toxicities. The clinical outcomes of these 12 patients appear comparable to data from prospective studies conducted at proton centers across Japan.
Conclusion:
SS-PBT shows promise as a treatment option for surgery-inaccessible hepatocellular carcinoma.
